TriangleNCT02837042 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- days
- Interval / dispersion
- Inter-Quartile Range
- Time frame
- From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
What was measured
Length of subject survival after starting study treatment
Analysis population: Due to poor accrual, low sample size, and higher number of patients censored, the 95% CI for median OS and PFS could not be determined.
Groups in this outcome
Pembrolizumab 200 mg
Once eligibility is confirmed, the patient will start treatment cycles with Pembrolizumab at 200 mg given intravenously on the first day of each cycle. Each cycle corresponds to a duration of 3 weeks. Pembrolizumab: Pembrolizumab will be administered intravenously every 3 weeks.
| Group | Source count |
|---|---|
| Pembrolizumab 200 mg | 6 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pembrolizumab 200 mg | 307 | Not reported | NA | NA | The study was ended prematurely due to poor accrual and only two patients progressed while the rest were lost to follow up. The statistical analysis will not give a reliable range except median based on two findings |
Complete source fields
- classes
- categories
- measurements
- comment
- The study was ended prematurely due to poor accrual and only two patients progressed while the rest were lost to follow up. The statistical analysis will not give a reliable range except median based on two findings
- group Id
- OG000
- lower Limit
- NA
- upper Limit
- NA
- value
- 307
- denoms
- counts
- group Id
- OG000
- value
- 6
- units
- Participants
- description
- Length of subject survival after starting study treatment
- dispersion Type
- Inter-Quartile Range
- groups
- description
- Once eligibility is confirmed, the patient will start treatment cycles with Pembrolizumab at 200 mg given intravenously on the first day of each cycle. Each cycle corresponds to a duration of 3 weeks. Pembrolizumab: Pembrolizumab will be administered intravenously every 3 weeks.
- id
- OG000
- title
- Pembrolizumab 200 mg
- param Type
- MEDIAN
- population Description
- Due to poor accrual, low sample size, and higher number of patients censored, the 95% CI for median OS and PFS could not be determined.
- reporting Status
- POSTED
- time Frame
- From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- days
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice